Effect of famotidine and lansoprazole on serum phosphorus levels in hemodialysis patients on calcium carbonate therapy

2007 ◽  
Vol 68 (08) ◽  
pp. 93-98 ◽  
Author(s):  
C. Matsunaga ◽  
S. Izumi ◽  
T. Furukubo ◽  
M. Satoh ◽  
T. Yamakawa ◽  
...  
Keyword(s):  
Calcium Carbonate ◽  
Hemodialysis Patients ◽  
Serum Phosphorus ◽  
Phosphorus Levels

scholarly journals Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study

2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Kamyar Kalantar-Zadeh ◽  
Linda H. Ficociello ◽  
Vidhya Parameswaran ◽  
Nicolaos V. Athienites ◽  
Claudy Mullon ◽  
...  
Keyword(s):  
Serum Albumin ◽  
Dietary Intake ◽  
Phosphate Binder ◽  
Clinical Care ◽  
Elevated Serum ◽  
Hemodialysis Patients ◽  
Serum Phosphorus ◽  
Pill Burden ◽  
Historical Cohort ◽  
Phosphorus Levels

Abstract Background Elevated serum phosphorus concentrations are common among maintenance hemodialysis patients. Protein is a major source of dietary phosphate, but restriction of protein intake can result in hypoalbuminemia and protein-energy wasting. We hypothesized that sucroferric oxyhydroxide (SO), a potent phosphate binder with a low pill burden, may reduce serum phosphorus levels in hemodialysis patients with hypoalbuminemia without adversely impacting albumin levels or dietary intake of protein. Methods We retrospectively examined de-identified data from 79 adult, in-center hemodialysis patients with baseline hypoalbuminemia (≤ 3.5 g/dL) switched to SO as part of routine clinical care for at least 1 year. Temporal changes (3-month intervals from baseline through Q4) in phosphate binder pill burden, serum phosphorous levels, nutritional markers, and equilibrated Kt/V were analyzed. Data from a matched reference group of non-hypoalbuminemic patients (N = 79) switched to SO were also examined. Results SO therapy was associated with a mean reduction of 45.7 and 45.1% in daily phosphate binder pill burden, and a mean reduction of 0.4 mg/dL and 0.51 mg/dL in serum phosphorus levels for the hypoalbuminemic and non-hypoalbuminemic patients, respectively. Hypoalbuminemic patients demonstrated significant increases in mean serum albumin levels from 3.50 mg/dL at baseline to 3.69, 3.74, 3.70, and 3.69 mg/dL during Q1 through Q4, respectively (P < 0.0001), whereas serum albumin levels remained unchanged in the non-hypoalbuminemic group. Conclusions Both hypoalbuminemic and non-hypoalbuminemic patients switching to SO exhibited significant reductions in serum phosphorus concentrations and daily phosphate binder pill burden. Among hypoalbuminemic patients, the initiation of SO therapy was also associated with increases in serum albumin, suggesting therapy may have allowed patients to increase their dietary intake of protein.

Additional Reduction in Serum Phosphorus Levels by Pulverized Lanthanum Carbonate Chewable in Hemodialysis Patients

2013 ◽  
Vol 17 ◽  
pp. 54-59 ◽  
Author(s):  
Tetsuri Yamashita ◽  
Tetsuya Ogawa ◽  
Masaki Takahashi ◽  
Tetsuya Mitsuhashi ◽  
Junichi Shizuku ◽  
...  
Keyword(s):  
Hemodialysis Patients ◽  
Lanthanum Carbonate ◽  
Serum Phosphorus ◽  
Additional Reduction ◽  
Phosphorus Levels

Phosphorus Counting Table for the control of serum phosphorus levels without phosphate binders in hemodialysis patients

2019 ◽  
Vol 32 ◽  
pp. 153-157 ◽  
Author(s):  
Vivianne Rêis Bertonsello-Catto ◽  
Leandro Junior Lucca ◽  
José Abrão Cardeal da Costa
Keyword(s):  
Hemodialysis Patients ◽  
Serum Phosphorus ◽  
Phosphate Binders ◽  
Phosphorus Levels

scholarly journals Conhecimento sobre hiperfosfatemia, ingestão alimentar e níveis séricos de fósforo de pacientes em hemodiálise / Knowledge about hyperphosphatemia, food intake and serum phosphorus levels in hemodialysis patients

2021 ◽  
Vol 7 (9) ◽  
pp. 90750-90765
Author(s):  
Karina Fernanda Genier Murari Fernandes ◽  
Leia Silva Geraldo ◽  
Fernanda Alves Da Silva ◽  
Janaina da Conceição Alves Lemos ◽  
Christiane Ishikawa Ramos
Keyword(s):  
Food Intake ◽  
Hemodialysis Patients ◽  
Serum Phosphorus ◽  
Phosphorus Levels

scholarly journals Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia

2021 ◽  
pp. 1-11
Author(s):  
Takashi Shigematsu ◽  
Yotaro Une ◽  
Kazuaki Ikejiri ◽  
Hironori Kanda ◽  
Masafumi Fukagawa ◽  
...  
Keyword(s):  
Placebo Group ◽  
Hemodialysis Patients ◽  
Serum Phosphorus ◽  
Phosphate Binders ◽  
Therapeutic Effects ◽  
Efficacy And Safety ◽  
Phosphorus Level ◽  
Serum Phosphorus Level ◽  
The Mean ◽  
Phosphorus Levels

<b><i>Introduction:</i></b> Phosphate binders are used to treat hyperphosphatemia. Some patients have inappropriately controlled serum phosphorus levels, which may occur for many reasons, including a high pill burden and adverse events (AEs). Tenapanor selectively inhibits the passive paracellular transfer of phosphate in the gastrointestinal tract, thereby reducing serum phosphorus levels. This novel mechanism of action may contribute to improved phosphate management. The efficacy and safety of tenapanor have not been evaluated in Japanese patients with high serum phosphorus levels despite treatment with phosphate binders. This study aimed to assess the efficacy and safety of add-on tenapanor therapy for reducing serum phosphorus levels in this population. <b><i>Methods:</i></b> This multicenter, double-blind, randomized, placebo-controlled trial enrolled patients with refractory hyperphosphatemia undergoing hemodialysis. Patients were randomly assigned in a 1:1 ratio to receive tenapanor or placebo as an add-on to their phosphate binder regimen for 6 weeks. Change in serum phosphorus levels at week 6 (day 43) compared with the baseline value (day 1, week 0) (primary endpoint), achievement of target serum phosphorus levels (serum phosphorus level ≤6.0 or ≤5.5 mg/dL), and safety, based on all AEs and drug-related AEs, were among the outcomes evaluated. <b><i>Results:</i></b> In total, 24 patients were randomly assigned to the placebo group and 23 to the tenapanor group. The mean serum phosphorus level decreased from 7.01 mg/dL on day 1 to 6.69 mg/dL on day 43 in the placebo group and from 6.77 mg/dL on day 1 to 4.67 mg/dL on day 43 in the tenapanor group. In the placebo and tenapanor groups (modified intent-to-treat population), the mean (standard deviation) change in the serum phosphorus level at day 43 (last observation carried forward [LOCF]) was 0.08 (1.52) mg/dL and −1.99 (1.24) mg/dL, respectively, with a between-group difference of −2.07 (95% confidence interval: −2.89, −1.26; <i>p</i> &#x3c; 0.001). The target achievement rate (serum phosphorus level ≤6.0 mg/dL at week 6 [LOCF]) was 37.5 and 87.0% in the placebo and tenapanor groups, respectively. Diarrhea was the most common drug-related AE, and it occurred in 8.3 and 65.2% of patients in the placebo and tenapanor groups, respectively. No specific AEs were observed with add-on tenapanor or with phosphate binders. <b><i>Discussion/Conclusion:</i></b> Therapy with existing phosphate binders and add-on tenapanor resulted in a significant decrease in serum phosphorus level compared with the placebo group in patients with refractory hyperphosphatemia despite treatment with phosphate binders. No new safety signals were raised, and add-on tenapanor was generally well tolerated.

Sign in / Sign up

Export Citation Format

Share Document